Dr Ailawadhi on Iopofosine I-131 in Waldenström Macroglobulinemia
January 5th 2024Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses how the investigational agent iopofosine I-131 may address unmet needs for patients with Waldenström macroglobulinemia.
Advani Spotlights Clinical Trial Implications Across Breast Cancer Subtypes
January 4th 2024Pooja Advani, MBBS, MD, details key advancements and the significance of pivotal trials that were presented by her colleagues at a recent OncLive® State of the Science Summit™ on breast cancer, which she chaired.
UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
December 27th 2023Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
December 20th 2023Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Lutetium Lu 177 Vipivotide Tetraxetan Addresses Unmet Need in Taxane-Naive mCRPC
Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.
Moonshot Cancer Initiative and MCED Consortium: Advancing Cancer Detection
November 14th 2023Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.
Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLC
October 26th 2023While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.